Skip to main content

Concurrent Use of Opioids and Benzodiazepines (COB)

CBE ID
3389
Endorsed
Endorsement Status
Endorsed
1.1 New or Maintenance
Maintenance
E&M Cycle
Spring 2021
Is Under Review
No
Next Planned Maintenance Review
Patient Safety Spring 2025
1.3 Measure Description

The percentage of individuals >=18 years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

A lower rate indicates better performance.

    • 1.5 Measure Type
      Process
      1.7 Electronic Clinical Quality Measure (eCQM)
      No
      1.8 Level Of Analysis
      Health Plan
      1.20 Testing Data Sources
      Claims Data
    • 1.14 Numerator

      The number of individuals from the denominator with concurrent use of opioids and benzodiazepines for >=30 cumulative days during the measurement year.

    • 1.15 Denominator

      The denominator includes individuals >=18 years of age with >=2 prescription claims for opioid medications on different dates of service and with >=15 cumulative days’ supply during the measurement year. Individuals with cancer, sickle cell disease, or in hospice are excluded.

    • Exclusions

      Individuals with cancer, sickle cell disease, or in hospice at any point during the measurement year are excluded from the denominator.

    • 1.13a Data dictionary not attached
      No
    • Most Recent Endorsement Activity
      Endorsed Patient Safety Spring Cycle 2021
      Initial Endorsement
      Last Updated
    • Risk Adjustment
      No risk adjustment or risk stratification
      Risk adjustment approach
      Off
      Risk adjustment approach
      Off
      Conceptual model for risk adjustment
      Off
      Conceptual model for risk adjustment
      Off